FI954536L - Eristettyjä nukleiinihappomolekyylejä, jotka koodittavat kasvainhyljintäantigeenin esiastetta MAGE-3, ja niiden hyötykäyttö - Google Patents

Eristettyjä nukleiinihappomolekyylejä, jotka koodittavat kasvainhyljintäantigeenin esiastetta MAGE-3, ja niiden hyötykäyttö Download PDF

Info

Publication number
FI954536L
FI954536L FI954536A FI954536A FI954536L FI 954536 L FI954536 L FI 954536L FI 954536 A FI954536 A FI 954536A FI 954536 A FI954536 A FI 954536A FI 954536 L FI954536 L FI 954536L
Authority
FI
Finland
Prior art keywords
utility
nucleic acid
acid molecules
isolated nucleic
molecules encoding
Prior art date
Application number
FI954536A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI954536A0 (fi
FI954536A7 (fi
Inventor
Beatrice Gaugler
Den Eynde Benoit Van
Thierry Boon-Falleur
Der Bruggen Pierre Van
Original Assignee
Ludwig Inst Cancer Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ludwig Inst Cancer Res filed Critical Ludwig Inst Cancer Res
Publication of FI954536A0 publication Critical patent/FI954536A0/fi
Publication of FI954536A7 publication Critical patent/FI954536A7/fi
Publication of FI954536L publication Critical patent/FI954536L/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Casings For Electric Apparatus (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
FI954536A 1993-03-26 1994-03-17 Eristettyjä nukleiinihappomolekyylejä, jotka koodittavat kasvainhyljintäantigeenin esiastetta MAGE-3, ja niiden hyötykäyttö FI954536L (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/037,230 US6235525B1 (en) 1991-05-23 1993-03-26 Isolated nucleic acid molecules coding for tumor rejection antigen precursor MAGE-3 and uses thereof
PCT/US1994/002877 WO1994023031A1 (fr) 1993-03-26 1994-03-17 Molecules d'acide nucleique isolees codant le precurseur de l'antigene anti-tumoral mage-3 et leurs utilisations

Publications (3)

Publication Number Publication Date
FI954536A0 FI954536A0 (fi) 1995-09-25
FI954536A7 FI954536A7 (fi) 1995-09-25
FI954536L true FI954536L (fi) 1995-09-25

Family

ID=21893179

Family Applications (1)

Application Number Title Priority Date Filing Date
FI954536A FI954536L (fi) 1993-03-26 1994-03-17 Eristettyjä nukleiinihappomolekyylejä, jotka koodittavat kasvainhyljintäantigeenin esiastetta MAGE-3, ja niiden hyötykäyttö

Country Status (15)

Country Link
US (6) US6235525B1 (fr)
EP (1) EP0690915B1 (fr)
JP (1) JP3594307B2 (fr)
KR (1) KR100288749B1 (fr)
CN (1) CN1110556C (fr)
AT (1) ATE229072T1 (fr)
AU (1) AU685790B2 (fr)
CA (1) CA2159098C (fr)
DE (1) DE69431834T2 (fr)
FI (1) FI954536L (fr)
NO (1) NO953699L (fr)
NZ (1) NZ263693A (fr)
TW (1) TW432111B (fr)
WO (1) WO1994023031A1 (fr)
ZA (1) ZA941644B (fr)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5925729A (en) * 1991-05-23 1999-07-20 Ludwig Institute For Cancer Research Tumor rejection antigen precursors, tumor rejection antigens and uses thereof
USRE40089E1 (en) * 1991-05-23 2008-02-19 Ludwig Institute For Cancer Research Nucleic acid molecules encoding the MAGE-1 tumor rejection antigen precursor
US6060257A (en) * 1994-06-03 2000-05-09 Ludwig Institute For Cancer Research Tumor rejection antigens presented by HLA-B44 molecules, and uses thereof
US5587289A (en) * 1995-03-14 1996-12-24 Ludwig Institute For Cancer Research Isolated nucleic acid molecules which are members of the MAGE-Xp family and uses thereof
AU7440196A (en) * 1995-10-12 1997-04-30 Chiron Corporation Baboon mage-3 homologs, dna encoding the homologs, and a process for their use
UY24367A1 (es) * 1995-11-23 2000-10-31 Boehringer Ingelheim Int Vacunas contra tumores y procedimiento para su produccion
RS50101B (sr) 1996-02-24 2009-01-22 Boehringer Ingelheim International Gmbh., Farmaceutski preparati za imunomodulaciju
FR2746110B1 (fr) * 1996-03-14 1998-04-17 Methode de traitement par therapie genique des tumeurs humaines et virus recombinants correspondants
US6027924A (en) * 1997-04-25 2000-02-22 Ludwig Institute For Cancer Research Isolated nucleic acid molecule coding for tumor rejection antigen precursor MAGE-C1 and uses thereof
US6716809B1 (en) 1997-09-12 2004-04-06 Ludwig Institute For Cancer Research Mage-A3 peptides presented by HLA class molecules
US6291430B1 (en) 1997-09-12 2001-09-18 Ludwig Institute For Cancer Research Mage-3 peptides presented by HLA class II molecules
US5965535A (en) 1997-09-12 1999-10-12 Ludwig Institute For Cancer Research Mage-3 peptides presented by HLA class II molecules
PT1053325E (pt) 1998-02-05 2006-05-31 Glaxosmithkline Biolog Sa Derivados de antigenios associados a tumores da familia mage e, sequencias de acidos nucleicos que os codificam, utilizados para a preparacao de proteinas de fusao e de composicoes para vacinacao.
US6446109B2 (en) * 1998-06-29 2002-09-03 Sun Microsystems, Inc. Application computing environment
EP1181304B1 (fr) * 1999-04-08 2007-10-10 Antisoma Research Limited Procede inhibant la proliferation d'oligonucleotides riches en guanosine et procede de liaison desdits oligonucleotides a la nucleoline
US20080318889A1 (en) * 1999-04-08 2008-12-25 Antisoma Research Limited Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin
US7960540B2 (en) * 1999-04-08 2011-06-14 Advanced Cancer Therapeutics, Llc Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin
US8114850B2 (en) * 1999-04-08 2012-02-14 Advanced Cancer Therapeutics, Llc Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin
US20080318890A1 (en) * 1999-04-08 2008-12-25 Antisoma Research Limited Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin
IT1312568B1 (it) * 1999-05-21 2002-04-22 Genera Spa Peptidi immunogenici e loro uso.
ATE395930T1 (de) 1999-10-22 2008-06-15 Aventis Pasteur Verfahren zur erregung und/oder verstärkung der immunantwort gegen tumorantigene
JP3603138B2 (ja) * 2000-02-18 2004-12-22 独立行政法人理化学研究所 細胞死抑制タンパク質
DK1282702T3 (da) * 2000-05-10 2007-04-02 Sanofi Pasteur Ltd Immunogene polypeptider, som er kodet af KAGE-minigener, og anvendelser deraf
AU2001272491A1 (en) * 2000-06-26 2002-01-08 Smithkline Beecham Biologicals (S.A.) Triple fusion proteins comprising ubiquitin fused between thioredoxin and a polypeptide of interest
WO2002083945A2 (fr) 2001-04-12 2002-10-24 Imperial College Innovations Limited Diagnostic et traitement du cancer
US7049413B2 (en) 2001-05-18 2006-05-23 Ludwig Institute For Cancer Research MAGE-A3 peptides presented by HLA class II molecules
US20030148973A1 (en) * 2001-05-23 2003-08-07 Peter Emtage MAGE-A1 peptides for treating or preventing cancer
US20030113919A1 (en) * 2001-08-17 2003-06-19 Aventis Pasteur, Ltd. Immunogenic targets for melanoma
EP1864691B1 (fr) 2002-04-09 2011-07-20 Sanofi Pasteur Limited Acide nucléique ACE modifié et vecteurs d'expression
AU2004280608B2 (en) * 2002-04-09 2012-04-05 Sanofi Pasteur, Inc. Modified CEA/B7 vector
WO2004037284A1 (fr) * 2002-10-22 2004-05-06 Sanofi Pasteur Limited Vaccins anticancereux et cytokines a haute dose utilisees comme adjuvants
DE10347710B4 (de) 2003-10-14 2006-03-30 Johannes-Gutenberg-Universität Mainz Rekombinante Impfstoffe und deren Verwendung
US20070154889A1 (en) * 2004-06-25 2007-07-05 Veridex, Llc Methods and reagents for the detection of melanoma
DE102005046490A1 (de) 2005-09-28 2007-03-29 Johannes-Gutenberg-Universität Mainz Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen
GB0700284D0 (en) * 2007-01-08 2007-02-14 Glaxosmithkline Biolog Sa Combination therapy
NZ599777A (en) 2007-11-07 2013-09-27 Celldex Therapeutics Inc Antibodies that bind human dendritic and epithelial cell 205 (DEC-205)
US20090131351A1 (en) * 2007-11-16 2009-05-21 Antisoma Research Limited Methods, compositions, and kits for modulating tumor cell proliferation
AU2009223727B2 (en) 2008-03-14 2014-09-11 Sanofi Pasteur Biologics, Llc Replication-defective flavivirus vaccines and vaccine vectors
EP3165540A1 (fr) 2010-04-13 2017-05-10 Celldex Therapeutics, Inc. Anticorps liant un cd27 humain et leurs utilisations
HRP20211595T1 (hr) 2011-05-24 2022-01-21 BioNTech SE Individualizirana cjepiva protiv raka
GB201120860D0 (en) 2011-12-05 2012-01-18 Cambridge Entpr Ltd Cancer immunotherapy
WO2013143555A1 (fr) 2012-03-26 2013-10-03 Biontech Ag Formulation d'arn pour immunothérapie
WO2014082729A1 (fr) 2012-11-28 2014-06-05 Biontech Ag Vaccins individualisés contre le cancer
WO2014140938A2 (fr) 2013-03-14 2014-09-18 Centre Hospitalier Universitaire Vaudois Méthodes immunologiques
WO2014180490A1 (fr) 2013-05-10 2014-11-13 Biontech Ag Prédiction de l'immunogénicité d'épitopes de lymphocytes t
PT3151921T (pt) 2014-06-06 2019-11-21 Bristol Myers Squibb Co Anticorpos contra recetor do fator de necrose tumoral induzido por glicocorticoide e utilizações dos mesmos
EP3194970B1 (fr) 2014-09-10 2021-07-28 F. Hoffmann-La Roche AG Plateforme de criblage de peptides immunogenes mutants
WO2016045732A1 (fr) 2014-09-25 2016-03-31 Biontech Rna Pharmaceuticals Gmbh Formulations stables de lipides et de liposomes
WO2016094309A1 (fr) 2014-12-10 2016-06-16 Myosotis Inhibition de la signalisation de tnf en immunothérapie du cancer
WO2016128060A1 (fr) 2015-02-12 2016-08-18 Biontech Ag Prédiction des épitopes de lymphocytes t utiles pour la vaccination
US20180044429A1 (en) 2015-03-09 2018-02-15 Celldex Therapeutics, Inc. Cd27 agonists
TN2019000101A1 (en) 2015-05-29 2020-07-15 Bristol Myers Squibb Co Antibodies against ox40 and uses thereof.
IL274572B2 (en) 2015-07-16 2024-01-01 Biolinerx Ltd Compositions and methods for treating cancer
WO2017059902A1 (fr) 2015-10-07 2017-04-13 Biontech Rna Pharmaceuticals Gmbh Séquences utr 3' permettant la stabilisation d'arn
GB201519340D0 (en) 2015-11-02 2015-12-16 Cambridge Entpr Ltd Methods of T-lymphocyte expansion
GB201519481D0 (en) 2015-11-04 2015-12-16 Cancer Rec Tech Ltd Immunomodulatory antibodies
BR112018010172A2 (pt) 2015-11-19 2018-11-21 Bristol Myers Squibb Co anticorpos contra receptor de fator de necrose de tumor induzido por glicocorticoide (gitr) e usos dos mesmos
US12297266B2 (en) 2016-04-18 2025-05-13 Celldex Therapeutics, Inc. Agonistic antibodies that bind human CD40 and uses thereof
GB201616238D0 (en) 2016-09-23 2016-11-09 Adaptimmune Ltd Modified T cells
LT3565579T (lt) 2017-01-05 2023-09-11 Kahr Medical Ltd. Pd1-41bbl sulietas baltymas ir jo panaudojimo būdai
PT3565828T (pt) 2017-01-05 2022-02-08 Kahr Medical Ltd Proteína de fusão sirp1 alfa-41bbl e seus métodos de utilização
GB201700345D0 (en) 2017-01-09 2017-02-22 F-Star Beta Ltd Conditional agonists of immune responses
IL250916A0 (en) 2017-03-02 2017-06-29 Geiger Benjamin Methods for growing t cells in culture and their use
WO2018224166A1 (fr) 2017-06-09 2018-12-13 Biontech Rna Pharmaceuticals Gmbh Procédés de prédiction de l'utilité de modifications d'acides aminés spécifiques d'une maladie pour l'immunothérapie
WO2019006003A1 (fr) 2017-06-27 2019-01-03 The Trustees Of Princeton University Compositions et procédés pour améliorer une immunothérapie
GB201713078D0 (en) 2017-08-15 2017-09-27 Adaptimmune Ltd T Cell Modification
JP2021515588A (ja) 2018-01-26 2021-06-24 ケンブリッジ エンタープライズ リミティッド ペプチド交換蛋白質
US12134638B2 (en) 2018-07-11 2024-11-05 Kahr Medical Ltd. SIRPalpha-4-1BBL variant fusion protein and methods of use thereof
GB201811404D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Anti-CD137 Antibodies
GB201811410D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd OX40 Binding molecules
GB201811408D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd CD137 Binding Molecules
WO2020041662A1 (fr) 2018-08-24 2020-02-27 The Trustees Of Princeton University Immunothérapie avec expression d'enzyme métabolique
GB201820444D0 (en) 2018-12-14 2019-01-30 Adaptimmune Ltd Marker for T cell expansion
US20220267409A1 (en) 2019-07-11 2022-08-25 Kahr Medical Ltd. Heterodimers and methods of use thereof
GB201911954D0 (en) 2019-08-20 2019-10-02 Adaptimmune Ltd Lentiviral transduction methods
US20230048361A1 (en) 2019-12-31 2023-02-16 Kahr Medical Ltd. Methods of culturing t cells and uses of same
WO2021137231A1 (fr) 2019-12-31 2021-07-08 Kahr Medical Ltd. Procédés de culture de lymphocytes t avec un polypeptide de fusion 4-1bbl et leurs utilisations
CN111647066B (zh) * 2020-07-01 2020-12-18 维肽瀛(上海)生物技术有限公司 Wt1多肽肿瘤抑制剂
IL276599A (en) 2020-08-09 2022-03-01 Yeda Res & Dev T cell receptor unique to mage-a1 and its uses
CN117157318A (zh) 2020-12-30 2023-12-01 免疫治疗有限公司 抗hvem抗体
GB202303250D0 (en) 2023-03-06 2023-04-19 King S College London Method and compounds
WO2025155971A1 (fr) 2024-01-19 2025-07-24 Immunomic Therapeutics, Inc Anticorps de récepteur du récepteur anti-activine 1c (alk-7)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61104788A (ja) * 1984-10-26 1986-05-23 Teijin Ltd 核酸塩基配列
US5342774A (en) * 1991-05-23 1994-08-30 Ludwig Institute For Cancer Research Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1
JPH05246889A (ja) * 1992-03-05 1993-09-24 Seitai Chiyousetsu Kenkyusho:Kk 制癌方法および制癌剤
US5405940A (en) * 1992-08-31 1995-04-11 Ludwig Institute For Cancer Research Isolated nonapeptides derived from MAGE genes and uses thereof

Also Published As

Publication number Publication date
AU6447594A (en) 1994-10-24
KR100288749B1 (ko) 2001-05-02
US6946289B1 (en) 2005-09-20
AU685790B2 (en) 1998-01-29
CN1093751A (zh) 1994-10-19
WO1994023031A1 (fr) 1994-10-13
CA2159098C (fr) 2003-04-29
FI954536A0 (fi) 1995-09-25
ATE229072T1 (de) 2002-12-15
US6025474A (en) 2000-02-15
FI954536A7 (fi) 1995-09-25
NO953699D0 (no) 1995-09-20
ZA941644B (en) 1994-10-12
JP3594307B2 (ja) 2004-11-24
EP0690915B1 (fr) 2002-12-04
TW432111B (en) 2001-05-01
CA2159098A1 (fr) 1994-10-13
EP0690915A1 (fr) 1996-01-10
US6235525B1 (en) 2001-05-22
EP0690915A4 (fr) 1997-11-12
US6552180B1 (en) 2003-04-22
CN1110556C (zh) 2003-06-04
US6565857B1 (en) 2003-05-20
DE69431834D1 (de) 2003-01-16
NZ263693A (en) 1996-07-26
US6599699B1 (en) 2003-07-29
DE69431834T2 (de) 2003-09-18
JPH08508402A (ja) 1996-09-10
NO953699L (no) 1995-11-20

Similar Documents

Publication Publication Date Title
FI954536A7 (fi) Eristettyjä nukleiinihappomolekyylejä, jotka koodittavat kasvainhyljin täantigeenin esiastetta MAGE-3, ja niiden hyötykäyttö
DE3687646D1 (de) Biosensor und dessen herstellung.
DE3682654D1 (de) Acylaminosiliciumverbindungen, deren verwendung und herstellung.
DE3864585D1 (de) Dns-molekule, codierend fuer non-a-non-b-hepatitis-antigene und ihre verwendung zur herstellung dieser antigene.
DE3667998D1 (de) Reaktivfarbstoffe, deren herstellung und verwendung.
DE3581578D1 (de) Antikoerper, herstellung und verwendung.
FI970115L (fi) Nukeliinihappoja sisältävä valmiste, sen valmistus ja käytöt
FI954360A7 (fi) Kasvaimen hyljintäantigeenin esiastetta koodittava nukseiinihappo
DE68903512D1 (de) Korrosionshemmendes pigment und dessen herstellung.
AU4903101A (en) Isolated nucleic acid molecules encoding cancer associated antigens, the antigens per se, and uses thereof
DE69110729D1 (de) Aluminiumpigment und dessen Herstellungsverfahren.
DE3581255D1 (de) Dns, deren herstellung und verwendung.
AU7198291A (en) Human monoclonal antibodies against rabies viruses, the production and the use thereof
DE3668326D1 (de) Reaktivfarbstoffe, deren herstellung und verwendung.
DE3687977D1 (de) Farbfilter hoechster genauigkeit mit ausgezeichneten eigenschaften und dessen herstellung.
DE3580432D1 (de) Hochmolekulare polyester, ihre herstellung und verwendung.
DE3669323D1 (de) Reaktivfarbstoffe, deren herstellung und verwendung.
FI961202L (fi) Grb3-3-geeni, sen variantteja ja niiden käyttöjä
DE3682491D1 (de) Immobilisierter c-peptid-antikoerper, seine herstellung und verwendung.
DE3889980D1 (de) Reaktivfarbstoffe, deren Herstellung und Verwendung.
DE3669518D1 (de) Vollaromatische polyester, deren herstellung und verwendung.
DE3673587D1 (de) Magnetronanode und deren herstellung.
DE69130845D1 (de) HLA-DR Antigen-Gen, dessen Nukleotidsequenz und Verwendung
FI964812A7 (fi) Kasvaintenhyljintäantigeenin esiastetta koodittava eristetty nukleiinihappomolekyyli ja sen käyttöjä
AU4264097A (en) Mage-10 encoding cdna, the tumor rejection antigen precursor mage-10, antibodies specific to the molecule, and uses thereof